SCHEMBL1544034

SCHEMBL1544034

COc1ccc(S(=O)(=O)Nc2cc(B3OC(C)(C)C(C)(C)O3)cnc2Cl)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.46
MTOR P42345 2/20 0.45
AKT1 P31749 1/20 0.45
PIK3CD O00329 3/20 0.44
FFAR4 Q5NUL3 2/20 0.44
PIK3R1 P27986 1/20 0.44
ALPL P05186 1/20 0.43
PIK3CG P48736 2/20 0.43
KEAP1 Q14145 2/20 0.43
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
SQSTM1 Q13501 1/20 0.43
NFE2L2 Q16236 1/20 0.43
PIK3CA P42336 1/20 0.42
PIK3CB P42338 1/20 0.42
CCR9 P51686 1/20 0.42
ALDH1A1 P00352 1/20 0.42
POLB P06746 1/20 0.42
GLO1 Q04760 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15462778 0.88 ALPL (0.51) LMNAMTORPIK3CDFFAR4PIK3R1
SCHEMBL409468 0.87 PIK3CD (0.53) MTORAKT1PIK3CDPIK3R1PIK3CA
SCHEMBL29556220 0.87 PIK3CD (0.53) MTORAKT1PIK3CDPIK3R1PIK3CA
SCHEMBL3115744 0.87 PIK3CD (0.57) MTORPIK3CDPIK3R1PIK3CGPIK3CA
SCHEMBL29555684 0.87 PIK3CD (0.57) MTORPIK3CDPIK3R1PIK3CGPIK3CA
SCHEMBL12724454 0.86 LMNA (0.42) LMNAMTORAKT1PIK3CDFFAR4
SCHEMBL28578763 0.86 PIK3CG (0.44) MTORPIK3CDPIK3R1ALPLPIK3CG
SCHEMBL15649467 0.85 LMNA (0.43) LMNAFFAR4ALPLKEAP1KMT2A
SCHEMBL17160484 0.84 LMNA (0.42) LMNAFFAR4ALPLKEAP1KMT2A
SCHEMBL22508714 0.83 ALPL (0.50) LMNAMTORPIK3CDPIK3R1ALPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2307400-B1 INHIBITORS OF PI3 KINASE AMGEN INC (US) 2014-04-23 EP disclosed
EP-2307400-B1 INHIBITORS OF PI3 KINASE AMGEN INC (US) 2014-04-23 EP disclosed
US-8415376-B2 Inhibitors of PI3 kinase AMGEN INC. (US) 2013-04-09 US disclosed
US-8415376-B2 Inhibitors of PI3 kinase AMGEN INC. (US) 2013-04-09 US disclosed
US-8415376-B2 Inhibitors of PI3 kinase AMGEN INC. (US) 2013-04-09 US disclosed
EP-2183232-B1 PI3 KINASE MODULATORS AND METHODS OF USE AMGEN INC (US) 2013-03-06 EP disclosed
US-20110092504-A1 INHIBITORS OF PI3 KINASE AMGEN INC. 2011-04-21 US disclosed
US-20110092504-A1 INHIBITORS OF PI3 KINASE AMGEN INC. 2011-04-21 US disclosed
US-7928140-B2 Benzothiazole PI3 kinase modulators for cancer treatment AMGEN INC. (US) 2011-04-19 US disclosed
EP-2307400-A2 INHIBITORS OF PI3 KINASE Amgen, Inc (US) 2011-04-13 EP disclosed
EP-2183232-A2 PI3 KINASE MODULATORS AND METHODS OF USE Amgen, Inc (US) 2010-05-12 EP disclosed
WO-2009155121-A2 INHIBITORS OF PI3 KINASE AMGEN INC. (US) 2009-12-23 WO disclosed
WO-2009155121-A2 INHIBITORS OF PI3 KINASE AMGEN INC. (US) 2009-12-23 WO disclosed
US-20090054405-A1 PI3 kinase modulators and methods of use AMGEN INC. (US) 2009-02-26 US disclosed
WO-2009017822-A2 PI3 KINASE MODULATORS AND METHODS OF USE AMGEN INC. (US) 2009-02-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054405-A1 PI3 kinase modulators and methods of use PIK3CA, PIK3C2A, PIK3C2B LMNA 2300/4885MTOR 37/4885AKT1 20/4885
US-20110092504-A1 INHIBITORS OF PI3 KINASE PIK3CA, PIK3R1, PIK3R5 LMNA 2214/4885MTOR 34/4885AKT1 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.